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Abstract
The known virulence factor of Rift Valley fever virus (RVFV), the NSs protein, counteracts the antiviral effects of the type I
interferon response. In this study we evaluated the expression of several genes in the liver and spleen involved in innate and
adaptive immunity of mice immunized with a RVFV recombinant nucleocapsid protein (recNP) combined with Alhydrogel
adjuvant and control animals after challenge with wild type RVFV. Mice immunized with recNP elicited an earlier IFNb
response after challenge compared to non-immunized controls. In the acute phase of liver infection in non-immunized mice
there was a massive upregulation of type I and II interferon, accompanied by high viral titers, and the up- and
downregulation of several genes involved in the activation of B- and T-cells, indicating that both humoral and cellular
immunity is modulated during RVFV infection. Various genes involved in pro-inflammatory responses and with pro-
apoptotic effects were strongly upregulated and anti-apoptotic genes were downregulated in liver of non-immunized mice.
Expression of many genes involved in B- and T-cell immunity were downregulated in spleen of non-immunized mice but
normal in immunized mice. A strong bias towards apoptosis and inflammation in non-immunized mice at an acute stage of
liver infection associated with suppression of several genes involved in activation of humoral and cellular immunity in
spleen, suggests that RVFV evades the host immune response in more ways than only by inhibition of type I interferon, and
that immunopathology of the liver plays a crucial role in RVF disease progression.
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Introduction
Rift Valley fever virus (RVFV), a mosquito borne Phlebovirus of
the Bunyaviridae family, causes irregular but large outbreaks
characterized by high fatality rates in young domestic ruminants
and abortion storms in pregnant animals [1–3]. The RVFV RNA
genome consists of large (L) and medium (M) segments which are
in the negative sense, and a small (S) segment utilizing an
ambisense coding strategy. The L segment encodes a viral RNA-
dependent RNA polymerase, the M segment encodes two
structural glycoproteins, two non-structural proteins, and the S
segment encodes the nucleocapsid protein (NP) and a non-
structural protein (NSs) [4,5]. The NP is highly conserved and
constitutes the most immunodominant viral protein in the
Bunyaviridae family [6–11]. The NP associates with the viral
RNA-dependent RNA polymerase and viral RNA to form the
ribonucleoproteins (RNP) necessary for transcription and replica-
tion. The known virulence factor of RVFV, the NSs protein,
counteracts the antiviral effects of the type I interferon response.
Not much is known, however, about other molecular aspects
of RVFV pathogenicity. Although the nucleocapsid protein (NP)
of the virus does not induce production of neutralizing anti-
bodies, anti-NP antibodies have been shown to be protective in
mice [12–17]. Humoral responses against the RVFV glycoproteins
effectively neutralize the virus and are believed to solely protect
against challenge [14,16,18–20].
RVFV is sensitive to the actions of type I interferons [21–24]
but it has developed several counteracting mechanisms. The NSs
protein of RVFV interacts with a repressor complex (Sin3A/
NCoR/HDAC) to inhibit transcriptional activation of the IFNb
gene [25,26]. A more general shutdown of cellular gene expression
is caused by interaction of NSs with the p44 subunit of the basal
transcription factor II H (TFIIH), resulting in reduced transcrip-
tional activity in RVFV infected cells [27]. The NSs has also been
shown to act on a post-translational level by degrading Protein
Kinase R (PKR) [28]. Interferon gamma (IFNc) is a strong
immunoregulator and has direct antiviral properties, but its role in
the protection of the host against RVFV infection is debatable
[29]. A study in rhesus monkeys showed that prophylactic
treatment with recombinant human IFNc before RVFV infection
protected monkeys from clinical disease and decreased viremia
significantly [30]. However, there was no marked difference in
pathogenicity of RVFV MP-12 or Clone-13 in wild type mice
compared to mice deficient in IFNc receptor (IFNGR
2/2),
suggesting that NSs does not have the same inhibitory effect on
the type II interferon response (IFNc) as it has on the type I
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protein (NSm) was implicated in the pathogenesis of RVF by
acting as an anti-apoptotic protein [32].
Do Valle et al. [33] utilizing microarray and quantitative PCR
showed that a specific strain of mice, BALB/cByJ, was more
resistant to RVFV infection when compared to a wild mouse
strain, MBT/Pas. The study analyzed the expression of genes
involved in the innate immune response by infecting mouse
embryonic fibroblasts (MEF) isolated from both strains with
RVFV in vitro, with results indicating a more significant type I IFN
response in the BALB/cByJ MEFs.
The activation of adaptive immunity after RVFV infection at
gene expression level in the main target organ for RVFV
replication, the liver, as well as in the spleen which plays a very
important role in host immunity, has not been investigated. A
better understanding of the activation of memory humoral and
cellular immune responses in these organs might aid the
development of improved RVFV vaccines and identification of
genes and their products as useful targets for development of gene
therapy and antivirals. The role that anti-NP responses play in the
protection of vaccinated individuals against RVFV infection is also
not clearly understood.
The results from this study suggest that an earlier type I
interferon response in recNP/Alhydrogel immunized mice
contribute to decreased challenge virus replication, whereas
upregulation of genes with the ability to result in immunopathol-
ogy, combined with uncontrolled challenge virus replication, in
non-immunized mice probably contributed to liver damage and
morbidity, and downregulation of humoral and cellular immunity
in the spleen possibly contributed to immune evasion.
Results
Immune response elicited by recNP/Alhydrogel
immunization
The activation of either Th-1 cellular immunity, indicated by
IgG2A subclass expression, or Th-2 humoral immunity, indicated
by IgG1 subclass expression, was evaluated by testing serial bleeds
after recNP/Alhydrogel immunization. Strong total IgG and IgG1
subclass responses were detectable by day 7 after the first
immunization, with strong responses still detectable on the day
before the booster inoculation (day 12) and RVFV challenge (day
27 after the booster)(IgG: average=72.2 PP, standard devia-
tion=5.5 PP, OD405 nm=0.79; IgG1: average=46.7 PP, standard
deviation=5.3 PP, OD405 nm=0.47 on day 12 after the initial
immunization; IgG: average=129.9 PP, standard deviation=4.7
PP, OD405 nm=1.42; IgG1: average=131.3 PP, standard devia-
tion=12.0 PP, OD405 nm=1.31 on day 27 after the booster,
Figure 1). The IgG2A subclass response (IgG2A: average=16.8
PP, standard deviation=4.5 PP, OD405 nm=0.16) was weak
Figure 1. Anti-RVFV recNP response in recNP/Alhydrogel immunized mice. The total IgG (–N–), IgG1 subclass (—) and IgG2A subclass (–D–)
responses are shown, with error bars indicating the standard deviations from the mean PP values of three biological replicates per time point.
doi:10.1371/journal.pone.0025027.g001
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immunization (PP ratio of IgG1:IgG2A=2.8:1). On the day
before RVFV challenge (IgG2A: average=23.4 PP, standard
deviation=4.2 PP, OD405 nm=0.22), a weak IgG2A response was
still detectable(PP ratio of IgG1:IgG2A=5.6:1) (Figure 1).
Dynamics of gene expression and virus load in livers and
spleens of immunized and control mice
The normalized expression of IL-10, IFNc and IFNb was
analyzed at 3, 6, 12, 24, 72 and 120 hours post RVFV infection in
liver and spleen tissue of recNP immunized, and non-immunized
adjuvant and PBS control mice. The results are shown in
Figure 2a–f.
The expression of IL-10 was upregulated with statistical
significance (4.5 fold, p,0.01) in adjuvant control mice but
normal in recNP immunized mice at 3 hours p.i. in the liver
(Figure 2a). At 72 and 120 hours p.i., however, IL-10 expression
was massively upregulated in the adjuvant (72 hours, 808.3 fold,
p=0.033; 120 hours, 55.0 fold, p,0.01) and PBS control groups
(72 hours, 243.3 fold, p,0.01; 120 hours, 99.3 fold, p=0.034),
and upregulated to a lesser extent in immunized mice (72 hours,
24.4 fold, p,0.01; 120 hours, 24.3 fold, p=0.033) in the liver
(Figure 2a). In the spleen expression of IL-10 was only upregulated
significantly at 72 hours p.i. in control mice (adjuvant 46.0 fold,
p,0.01; PBS 55.0 fold, p,0.01) (Figure 2b).
The expression of IFNc was normal in all mice livers at 3 hours,
but upregulated in all groups at 6 hours (recNP immunized, 17.2
fold, p,0.01; adjuvant control, 11.7 fold, p,0.01; PBS control,
9.3 fold, p,0.01), 72 hours (recNP immunized, 8.4 fold, p=0.03;
adjuvant control, 5.8 fold, p=0.03; PBS control, 4.4 fold, p=0.03)
and 120 hours p.i. (recNP immunized, 23.4 fold, p=0.03; adjuvant
control 224.0 fold, p,0.01; PBS control 237.0 fold, p=0.03)
(Figure 2c). Expression of IFNc remained unaltered in spleen
tissue (Figure 2d).
At 3 hours post infection (p.i.) the expression of the IFNb gene
was significantly upregulated in the livers (7.7 fold, p=0.03) and
spleens (12.0 fold, p=0.03) of recNP immunized mice, whereas
expression was normal in adjuvant control and PBS control groups
(Figure 2e–f). Expression of the gene remained upregulated in liver
of immunized mice until 12 hours p.i., after which it waned
(Figure 2e–f). In adjuvant control mice, IFNb was massively
upregulated at 72 hours p.i. in liver (2171.7 fold, p=0.03) and
spleen (542.3 fold, p,0.01), with similar results obtained in PBS
control mice liver (2524.1 fold, p=0.02) and spleen (510.3 fold,
Figure 2. (a–f). Fold changes in expression of IL10, IFNc and IFNb genes in tissues of mice after RVFV infection. RecNP immunized mice
(n=3 per time point) are indicated by solid black bars, adjuvant control mice (n=3 per time point) by grey bars and PBS control mice (n=3 per time
point) by white bars. The horizontal dotted lines indicate the cut-off values for upregulation (+2) or downregulation (22). The asterisk (*) indicates
where the P-value is smaller than or equal to 0.05 (statistically significant results). Standard error values are indicated by the error bars. Note the
differences in the Y-axis scales. The following time points are indicated: 3, 6, 12, 24, 72 and 120 hours.
doi:10.1371/journal.pone.0025027.g002
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remained upregulated in control mice liver.
The challenge virus was first detected in the tissues of adjuvant
control mice at 24 hours p.i. and, subsequently, at high titers in
adjuvant and PBS controls at 72 and 120 hours p.i. Low titer of
the virus was detected in liver of recNP-immunized mice only at
72 hours p.i. (10,000 fold lower than control mice). Surprisingly
the virus replicated to relatively higher titers in the spleen of
recNP-immunized mice, but only at 72 hours and still 100 fold
lower compared to control mice (Figure 3a–b).
The expression of genes involved in B- and T-cell
immunity and other immune functions at 72 hours
The expression of an array of 84 genes involved in B- and T-cell
immunity, and other immune functions, were analyzed in the liver
and spleen tissues of recNP-immunized, and non-immunized
adjuvant and PBS control mice at 72 hours post infection relative
to an age related normal control group. The list of genes tested,
fold change values for different groups and P-values are shown in
Table S1.
Only five genes were significantly upregulated and one down-
regulated in the liver of recNP-immunized mice, compared to 34
upregulated and nine downregulated in non-immunized adjuvant
control mice, and 37 upregulated and eight downregulated in non-
immunized PBS control mice (Table S1). There was an almost
100% overlap between the up- or downregulated genes in liver of
non-immunized adjuvant and PBS control mice, with only a few
genes not consistent between these two groups, most likely as a
result of the fold change in some of these genes being on the
borderline of the cut-off fold-change value, indicating that mock
Figure 3. (a–b). Mean viral loads in livers and spleens of RVFV infected mice. Groups, consisting of 3 mice per group per time point, are
indicated as: RecNP immunized (–N–), adjuvant control (–o–) and PBS control mice (–m–). Livers are indicated in panel a, and spleens in panel b.
doi:10.1371/journal.pone.0025027.g003
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immune responses after RVFV challenge. The expression of all 84
genes remained unaltered in the spleen of recNP immunized mice
compared to normal mice, whereas nine genes were significantly
upregulated and 20 downregulated in adjuvant control mice
spleens, compared to 11 upregulated and 20 downregulated in
PBS control mice spleens. Comparing tissues, only 10 genes were
similarly up- or downregulated in liver and spleen of adjuvant
control mice, whereas 45 genes yielded contrasting results between
tissues. Only 13 genes were similarly expressed in liver and spleen
of PBS control mice, compared to 44 genes which yielded
contrasting results between tissues (Table S1), indicating that there
was a tissue specific modulation of host gene expression in
response to RVFV infection. Selected genes that were significantly
up- or downregulated in any of the experimental groups and
indicating a clear difference or interesting similarity between
immunized and control mice were grouped according to known
effects on specific immune functions and shown in Figure 4 (a–b),
Figure 5 (a–f) and Figure 6 (a–d).
There was a significant upregulation of several genes in the liver
that have pro-apoptotic effects [34–42] in non-immunized
adjuvant and PBS control mice, whereas these genes were
normally expressed in recNP-immunized mice (Figure 4a,
Figure 5a). One gene in particular, encoding the early growth
response 1 protein (Egr-1) which is a transcription factor involved
in proliferation, differentiation and activation of cell death
pathways [43], that was upregulated in non-immunized mice
was downregulated in recNP-immunized mice. Only one gene
encoding the transcription factor RelB, part of the NF-KB family
of proteins and responsible for counter-regulating the effects of
NF-KB, was upregulated in liver of immunized and non-
immunized mice (Figure 5a) [40]. Several genes with anti-
apoptotic effects [44–49] were downregulated in the liver of
non-immunized control mice but normal in recNP-immunized
mice (Figure 5b). Most notable of these were the genes encoding
the prolactin receptor (Prlr), an anti-inflammatory protein known
to promote proliferation, protect against apoptosis and enhance
cell survival, and the WW domain containing E3 ubiquitin protein
ligase 1 (Wwp1), an anti-apoptotic protein playing a role in
proliferation [49]. There was also evidence of severe liver
inflammation [43,50–58] in non-immunized adjuvant and PBS
control mice, but not in recNP immunized mice (Figure 5c).
Despite this the gene encoding the anti-inflammatory cytokine IL-
10 was upregulated in all mice. The expression of osteopontin
(gene Spp1), important for wound healing, was upregulated
significantly in liver of non-immunized control mice, compared to
normal expression in immunized mice (Table S1) [58,59]. The
gene expressing the Cyclin-dependent kinase inhibitor P21
(Cdkn1a), a protein with pro- or anti-apoptotic effects and
normally upregulated in response to liver injury, was upregulated
in liver of all mice but more pronounced in non-immunized mice
(Table S1) [60]. The gene expressing the inducible nitric oxide
synthase (Nos2), an effector of the innate immune system targeting
viral proteases and inhibiting viral replication, was normal in liver
of recNP-immunized mice but upregulated in non-immunized
mice. Nitric oxide, a product of the Nos2 gene, is a radical
molecule that can become toxic under oxidative stress conditions
(Table S1) [61].
Both arms of the adaptive immune response, humoral (Th2) and
cellular (Th1) [45,50,52,62–74], were activated in liver of non-
immunized control mice, but normal in immunized mice, at
72 hours. The gene encoding the Phosphatidylinositol 3-kinase
catalytic delta polypeptide (Pik3cd), involved in the regulation of
B-cells and antibody production, was also upregulated in liver of
recNP-immunized mice indicating re-activation of humoral
immunity in mice recognizing one of the viral proteins as one it
has encountered before (Table S1) [75]. The genes encoding the
Dedicator of cyto-kinesis 2 (Dock2) protein and interleukin-12b,
which are involved in the development and induction of NKT
cells, were upregulated in liver of non-immunized control mice.
Some important genes were, however, downregulated in liver of
non-immunized control mice (Figure 5 d and Table S1). The gene
encoding the Cd1d1 antigen, which is important for the
presentation of antigens to, and activation of NKT cells, was
downregulated with statistical significance in non-immunized
control mice (Figure 5 d) [65,76,77]. The expression of the gene
encoding interleukin-7, necessary for B- and T-cell and NK cell
Figure 4. (a–b). Heat maps showing fold changes in liver and
spleen at 72 hours after RVFV infection. Expression of genes in
RecNP immunized, adjuvant control and PBS control mice are organized
according to function. Livers are indicated in panel a, and spleens in
panel b. The genes shown in orange are upregulated, those in blue are
downregulated and those in black or darker shades of orange and blue
have fold-change values between 22 and 2 and/or have p-values.0.05.
doi:10.1371/journal.pone.0025027.g004
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control mice (Figure 5b) [78]. The expression of surfactant protein
D (Sftpd), a member of the collectin family, important role player
in innate immunity and inhibitor of T lymphocyte proliferation,
was upregulated in liver of non-immunized control mice (Figure 5
d) [79]. The expression of the gene encoding the E3 Ubiquitin
Ligase Cbl-b, capable of negatively regulating T-cell activation,
was upregulated in liver of non-immunized control mice (Figure 5
d) [67,68,80]. The expression of the gene encoding interleukin-18,
responsible for biasing immunity towards Th-1 cellular immunity
and enhancing T-cell cytotoxicity, was downregulated in liver of
non-immunized control mice (Figure 5 d) [81]. The expression of
the suppressor of cytokine signaling 5 (Socs5), part of a family of
proteins that negatively regulate cytokine signaling [82], was
upregulated in liver of non-immunized control mice and the gene
encoding the immunoglobulin binding protein 1 (Igbp1), a
component of receptor cell signaling in B- and T-cells [45], was
downregulated in liver of non-immunized control mice. Other
genes (Cd81 and Pik3r1) involved in activation, signaling and
differentiation of B- and T-cells were also downregulated in liver of
non-immunized control mice (Table S1) [78,83].
An important role player in innate immunity, NK cells, was also
activated in liver of non-immunized control mice (Figure 5 f)
[64,84,85]. The gene encoding the histocompatibility 60 A
protein, a ligand for an activating receptor on NK cells [85],
was upregulated in non-immunized control mice. However,
expression of two important genes in NK cell activation and
maturation, IL-18 and the prolactin receptor (Prlr), were
downregulated in liver of non-immunized control mice [81,84].
The expression of three genes encoding Toll-like receptors, a
component of the innate immune system responsible for
recognizing conserved structures of pathogens, were analyzed
with only Tlr4 being upregulated in liver of non-immunized
control mice (Table S1) [86].
In contrast to the liver, there was not such a clear bias towards
apoptosis in the spleens of adjuvant and PBS control mice
(Figure 4b, Figure 6a). Only two genes with pro-apoptotic effects
were upregulated, and two genes with anti-apoptotic effects
downregulated in spleen of control mice. Interestingly expression
of Nos2 and Cd40, both with known pro-apoptotic effects and
upregulated in liver of control mice, were downregulated in spleen
of control mice. Similarly to liver, some genes with pro-
inflammatory effects were upregulated in the spleens of adjuvant
and PBS control mice (Figure 6b), except for the genes encoding
Nos2, Cd40 and Cd40 ligand. The expression of various genes
involved in the activation of B- and T-cell immunity were,
Figure 5. (a–f). Fold changes in expression of genes in the liver of experimental groups at 72 hours after RVFV infection. RecNP-
immunized mice (n=3) are indicated by solid black bars, adjuvant control mice (n=3) by grey bars and PBS control mice (n=3) by white bars. The
horizontal dotted lines indicate the cut-off values for upregulation (+2) or downregulation (22). The asterisk (*) indicates where the P-value is smaller
than or equal to 0.05 (statistically significant results). Standard deviation from the mean fold changes are indicated by the error bars.
doi:10.1371/journal.pone.0025027.g005
Protective Anti-RVFV NP Responses in Mice
PLoS ONE | www.plosone.org 6 September 2011 | Volume 6 | Issue 9 | e25027however, downregulated in the spleens of adjuvant and PBS
control mice (Figure 6c–d). The most notable of these were Cd40
and Cd40 ligand which are responsible for inducing effective
CD8+ cytotoxic T-lymphocyte (CTL) responses and activation of
B-cells for antibody production [51], and Cd8a and Cd8b1 which
are responsible for CTL activation (Figure 6c) [87]. Expression of
Complement receptor 2 (Cr2), which plays an important role in B-
cell activation and maturation, was also downregulated in spleen
of non-immunized control mice (Figure 6d).
Discussion
The immune evasion mechanisms known for RVFV are
directed against the type I interferon response [24,28,88] and
programmed cell death [29]. However, it was recently shown that
mice displaying an earlier and stronger type I interferon response
were less susceptible to RVFV infection than mice with a delayed
and partial response which suggests some additional evasive or
regulatory effects on innate or adaptive immune mechanisms
enabling its replication [33].
Immunization of mice with recNP combined with Alhydrogel
protected against disease and significantly reduced viral replication
[17]. A study by Lorenzo et al (2008) implicated a cellular (Th-1)
response to the RVFV NP as a protective mechanism [12],
however, our present data shows that immunization with recNP/
Alhydrogel induces Th-2 humoral immunity. The discrepant
outcome of the two studies might be explained by the fact that
Lorenzo et al (2008) used DNA vaccination [12], whereas in our
study a subunit antigen combined with adjuvant known to favour
Th-2 immunity, was used. Immunized mice launched an earlier
and stronger type I interferon response compared to non-
immunized mice which showed activation of several genes with
pro-apoptotic and pro-inflammatory effects, and suppression of
anti-apoptotic genes during acute phase of RVFV infection in the
liver. This possibly contributed to hepatic damage, which is the
main pathological feature of RVF [89]. The expression of several
genes involved in the activation and function of NK cells and B-
and T-lymphocytes were suppressed in infected mice, indicating
additional immune evasion tactics of RVFV.
The induction of expression of IFNb has been shown to occur in
vitro at 3–6 hours p.i [33], while in the livers and spleens of
immunized mice in this study it occurred at 3 hours p.i. Taking
into account that after host infection, the virus is likely conveyed to
the lymph nodes where it first replicates before it can spread to the
liver and other organs [2], our results show the ability of RVFV to
rapidly spread in the infected host. The expression of the same
gene was, however, not upregulated in the tissues of adjuvant and
PBS control mice early after infection. Type I interferon could not
Figure 6. (a–d). Fold changes in expression of genes in the spleen of experimental groups at 72 hours after RVFV infection. RecNP-
immunized mice (n=3) are indicated by solid black bars, adjuvant control mice (n=3) by grey bars and PBS control mice (n=3) by white bars. The
horizontal dotted lines indicate the cut-off values for upregulation (+2) or downregulation (22). The asterisk (*) indicates where the P-value is smaller
than or equal to 0.05 (statistically significant results). Standard deviation from the mean fold changes are indicated by the error bars.
doi:10.1371/journal.pone.0025027.g006
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not memory dependent. The fact, however, that the protective
anti-recNP responses shown here was largely humoral, but without
neutralizing effects, suggests that some other form of antibody
dependent mechanism, such as antibody-dependent cell-mediated
cytotoxicity (ADCC) or complement-dependent cytotoxicity
(CDC), might be responsible. It appears that the RVFV nucle-
ocapsid protein might be released from infected cells indepen-
dently from other viral proteins [13], and/or processed by the
infected host cell proteasome into peptides that are displayed on
their surface by MHC-1. Consequently these cells can be coated
with anti-NP IgG antibodies complexed with presented NP or
peptides, and become a target for ADCC or CDC. It has been
shown for influenza virus, with highly variable envelope
glycoprotein antigens but a conserved internal nucleoprotein, that
previous infection causes heterosubtypic immunity and that this is
due to antibodies against the NP involving CD8+ cells in an
antibody dependent manner [90]. The resultant lysis of RVFV
infected cells, that would otherwise have evaded the host innate
immune response and produced progeny virus because of the
inhibitory action of NSs on type I interferon might have resulted in
the activation of the type I interferon response in neighbouring
uninfected cells. The lysed cells would release dsRNA, a by-
product of viral replication and activator of type I interferon,
helping close-by uninfected cells to remain uninfected and thus
decrease virus spread [91]. It has been shown that an early type I
interferon response is protective against RVFV infection [18,33]
and it is thus highly likely that the early expression of IFNb in
immunized mice contributed to effective viral clearance and
protection. The excessive expression of IFNb, however, in control
mice later after infection (72–120 h) was not able to curb the
replication of the virus, as evidenced by high viral titers, and
probably contributed to the pathology in the liver and spleen. It
has been suggested that the role of IFNc in RVFV pathogenesis is
negligible [28] yet it has been shown in vivo that IFNc does act as
an antiviral against RVFV [27]. In our study expression of IFNc
was upregulated in all mice after infection, and there was only a
decrease in viral replication in immunized mice indicating that
IFNc did not play a significant role in protection. Also, the massive
expression of IFNc in control mice late after infection did not
contain viral replication in the liver and likely rather contributed
to liver pathology.
The improper expression of IL-10 during a viral infection might
contribute to immune escape events since IL-10 is an anti-
inflammatory and immunosuppressive cytokine that inhibits the
actions of Th-1 and NK cells, decreases antigen presentation and
limits the production of various important cytokines (i.e. IL-12, IL-
18 and TNF-a) [73]. It has been shown that IL-10 is upregulated
after West Nile virus (WNV) infection, and that IL-10 deficient
mice are less susceptible to WNV infection than mice expressing
the gene normally [92]. Dengue virus has also been shown to
replicate less efficiently when IL-10 expression is suppressed [93].
Some viruses even express IL-10 homologs to enable them to
modulate the host immune system and escape viral clearance [94–
96]. There was an early upregulation of IL-10 expression in liver
of adjuvant control mice when an anti-inflammatory response
would seem unnecessary. The early detection of replicating RVFV
in liver of adjuvant control mice might be contributed to immune
escape because of this early activation of IL-10. During the later
stages of infection when high level virus replication was noted in
non-immunized mice, the host upregulated expression of IL-10 to
counteract severe inflammation of tissues. A consequence of this,
however, is the suppression of various immune responses as
described above which possibly contributed to inefficient clearance
of virus in control mice or immune escape. The cytokines IL-10
and IFNc are counter-regulatory of each other with IFNc being
responsible for pathogen clearance and IL-10 minimizing
pathology [73], and therefore their relative expression levels can
be an indication of host immune response bias towards virus
clearance or minimizing immunopathology. At the acute phase of
infection and height of viral replication in non-immunized mice
the IL-10 to IFNc ratio was massively favoured towards IL-10,
indicating that these host responses were biased towards
decreasing inflammation and pathology rather than clearing the
virus, which most likely lead to ineffective viral clearance and high
virus titers still being detectable at 120 hours p.i. It was interesting
to note replication of virus to a much higher titer in spleen of
recNP immunized mice compared to liver. This, however, did not
result in any form of clinical disease in immunized mice which is
further evidence that early disease progression is proportional to
viral replication in the host liver and not necessarily other organs.
The activation of genes with pro-apoptotic and pro-inflamma-
tory effects and the suppression of genes with anti-apoptotic effects
in the liver of control mice as a result of uncontrolled viral
replication, most probably contributed to severe hepatic disease.
In the spleen activation of apoptosis and inflammation was not as
pronounced as in the liver of non-immunized mice at 72 hours p.i.
The liver is, however, the main target organ for viral replication,
the primary site for lesions and rapid severe hepatic damage is
probably responsible for the early clinical signs of RVF [89].
The overexpression of CD40, a member of the TNF receptor
superfamily and potent activator of nuclear factor kappa beta, in
the liver of non-immunized mice is of particular importance to
apoptosis and inflammation. Mice deficient in the expression of
CD40 have been shown to have improved survival during
bacterial sepsis as a result of decreased induction of IL-6, IL-10,
IL-12 and IFNc expression [97]. Contrary to upregulation in liver
the expression of CD40, as well as its ligand CD40L (CD154), was
downregulated in spleen of non-immunized mice during acute
infection. Apart from its role in apoptosis of hepatocytes, CD40
plays a very important role in mediating B- and T-cell responses
by controlling cytokine secretion, proliferation and differentiation
of B- and T-cells [51]. In addition to downregulation of CD40,
various other genes involved in B- and T-cell immunity were also
downregulated in the spleens of non-immunized mice. These
include NOS2, CD3e, IL7, IL18, CD8a,CD1D1, CD74, CR2 and
IL4. The spleen is a very important organ in the host immune
system and these results indicate that infection with RVFV has a
marked effect on the regulation of the host immune response on a
molecular level. It is possible that this broad downregulation of
humoral and cellular immunity could have resulted in uncon-
trolled replication of RVFV, since the virus was still detectable at
high titers 2 days later in non-immunized mice. The expression of
a TNF receptor superfamily ligand (Tnfsf14) was also upregulated
in liver of control mice, but normal in their spleens. This protein is
able to block TNFa-mediated apoptosis but not FAS-mediated
apoptosis, and is a co-stimulatory factor that enhances T-cell-
mediated immunity, leading to severe inflammation [41,98]. The
upregulation of the genes expressing the cell survival factor
osteopontin (Spp1) and the Cyclin-dependent kinase inhibitor P21
(Cdkn1a), which is upregulated in response to tissue injury
[99,100], is evidence of the host’s attempt to counteract the
damaging effects of the infection. P21 interacts, amongst others,
with the growth arrest and DNA damage-inducible gene 45
(Gadd45) [101], which was also upregulated in control mice.
Gadd45 has been implicated in DNA repair, apoptosis, regulation
of signal transduction and cell cycle control [102]. The NSs
protein of RVFV has been shown to interact with some specific
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structure and segregation [103]. Therefore it might be that these
DNA damage inducible proteins are upregulated in an attempt to
arrest the cell cycle of affected cells and prevent apoptosis. The fact
that P21 was upregulated in healthy recNP-immunized mice is
probably as a result of the very low level of viral replication in their
livers.
Although the expression of some genes were similarly regulated
during acute infection in the livers and spleens of non-immunized
mice, a number of genes were quite distinctly only up- or
downregulated in either liver or spleen, with some even being
upregulated in one tissue and downregulated in the other. This
distinct expression pattern between tissues is very likely a result of
the different cellular composition of the liver and spleen. The liver
consists mostly of hepatocytes, whereas the spleen consists of a red
pulp where red blood cells are filtered and monocytes are stored,
and a white pulp which consists of B- and T-lymphocytes. It seems
like the specific pattern of genes regulated during acute infection in
the liver actually contributed to liver pathology by enhancing
apoptosis and inflammation without being able to decrease viral
replication to less virulent levels. On the other hand in the spleen
the expression of genes involved in activation and modulation of
B- and T-cell immunity were altered during acute infection,
probably contributing to persistence of the virus in the host up to
120 hours. It was very interesting to note that, despite viral
replication to a relatively high level in spleen of recNP immunized
mice at 72 hours p.i., none of the 84 genes analyzed were up- or
downregulated in their spleens. The mechanism by which recNP
immunized mice can, 72 hours after infection, maintain expres-
sion levels of genes involved in immune activation similar to
expression levels in spleens of uninfected mice, despite viral
replication close to that in non-immunized mice where several
genes were altered, needs to be further investigated. It is, however,
fair to assume that this normal expression of genes involved in
immune activation at 72 hours p.i. contributed to efficient viral
clearance in immunized mice spleens, as is evidenced by the
absence of replicating virus at the next sampling point (120 h).
Further it is also fair to assume that the downregulation of B- and
T-cell immunity in non-immunized mice at 72 hours p.i.
contributed to the virus still replicating in their spleens at
120 hours p.i. Therefore, although not the main target organ of
RVFV and not as important for disease progression as the liver,
the spleen seems to be very important in regulating immune
responses and decreasing the replication of the virus with
dysregulation resulting in immune evasion. Further evidence of
the dysregulation of host immune responses by RVFV infection is
the fact that up- or downregulation of several genes (i.e. IL-18, IL-
12b, CD40 and SOCS5) indicate bias towards both Th1 and Th2
immunity in the same host.
In conclusion, the expression of type I IFN was upregulated in
the liver and spleen of immunized mice shortly after RVFV
challenge, compared to a delayed upregulation of the same gene in
non-immunized mice. In the acute phase of liver infection,
however, there was a massive upregulation of type I and II
interferon in the presence of high viral titers in non-immunized
mice associated with downregulation of several genes involved in
the activation of B- and T-cells in the spleen, compared to normal
expression in immunized mice. Furthermore various genes with
pro-apoptotic and pro-inflammatory effects were strongly upregu-
lated, and anti-apoptotic genes downregulated in liver of non-
immunized mice.
Host gene responses identified in this study may be useful targets
for the development of therapeutic interventions, e.g. suppressing
inflammatory and apoptotic effects of RVFV infection in the liver,
or limiting the suppression of B- and T-cell activation in the
spleen, and further aid the evaluation of subunit candidate
vaccines.
Materials and Methods
Ethics statement
This study was carried out in strict accordance with the
recommendations of the South African National Standards for the
Care and Use of Animals for Scientific Purposes (SANS
10386:2008) and the Guidelines for the Use and Care of Animals
in Experimental Education and other Scientific Purposes of the
University of the Witwatersrand, South Africa. The protocol was
approved by the University of the Witwatersrand Animal Ethics
Screening Committee (clearance certificate number AESC 2008/
16/4). Blood collection after immunization was done under
Ketamine/Xylazine anaesthesia, organ tissue collection after viral
challenge was done post-mortem after euthanasia with carbon
dioxide (CO2) asphyxiation, and all efforts were made to minimize
suffering.
Bacterial expression of recombinant RVFV N protein
Bacterial expression and purification of the recombinant N
protein was carried out as described previously [10].
Mouse immunization
Four-week old female BALB/cOlaHsd (Harlan Laboratories,
U.K LTD) mice were housed in groups of six in standard plastic
mouse cages with wood shaving bedding in a specific pathogen
free (SPF) facility during the immunization part of the experiment.
Group sizes were calculated so as to have three mice per group per
time point for each collection to enable statistical relevance. The
immunized group consisted of 60 mice each immunized with a
200 ml inoculum containing 70 mg RVFV recNP in combination
with Alhydrogel (Sigma, U.S.A). The adjuvant control group
consisted of 18 mice inoculated with Alhydrogel in PBS. The
placebo control group consisted of 18 mice which were inoculated
with PBS buffer. The normal control group consisted of 18 mice
that did not receive any inoculation during the immunization
experiment, but were included as an age related control group for
the gene expression experiment. All mice, except the age-related
normal control group, were inoculated subcutaneously (s.c.) and
received identical booster inoculums on day 14 after the initial
inoculation. Three mice from the recNP-immunized group were
anaesthetized by intramuscular inoculation with a combination of
Ketamine (35 mg/kg body mass) and Xylazine (5 mg/kg body
mass) and bled by cardiac puncture on each of the following days
post-immunization to monitor development of immune responses:
day 0, 3, 5, 7, 10 and 12 after the first immunization, and day 0, 3,
5, 7, 12, 18, 21 and 27 after the booster immunization.
Monitoring of immune response
Anti-recNP humoral responses were monitored by the indirect
ELISA which was done as described previously [17]. A mouse
serum with high levels of both IgG1 and IgG2A subclass
antibodies, generated by immunization with RVFV recNP
combined with SaponinQ adjuvant (Sigma, U.S.A) in a previous
study [17], was used as a positive control. The positive control
serum yielded similar optical density values at 405 nm for IgG
(1.094), IgG1 (1.01) and IgG2A (0.94) subclass antibodies at the
same dilution used for experimental sera (1:400). Optical density
(OD) was determined at 405 nm for each IgG subclass and means
calculated for duplicate measurements of each sample or control.
The mean OD values of samples for different IgG subclass
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the following calculation: PP=Mean OD sample/Mean OD
positive control 6100, using the OD values described above for
IgG, IgG1 and IgG2A to calculate PP values for those specific
subclasses. The PP values determined for each of the three
biological replicates at each time point (three mice sampled per
time point) were then used to calculate the biological mean PP
values and standard deviations (S.D.) at each sampling point for
the different IgG subclasses.
RVFV challenge
During the RVFV challenge phase of the experiment the mice
were housed as during the immunization part except for being
moved to a Biosafety level 3 animal facility.
Vero cells were cultivated in Eagles Minimal Essential Medium
(EMEM) (BioWhitaker, MD, U.S.A) containing L-Glutamine,
non-essential amino acids, antibiotics (100 IU penicillin, 100 mg
streptomycin and 0.25 mg amphotericin B) and 10% foetal bovine
serum (Gibco) and maintained at 37uCi n5 %C O 2 incubator. The
SPU22/118 KEN 07 strain of RVFV was isolated from a RVF
human case during the 2007 Kenyan epidemic [104].
Second passage of the virus, propagated in Vero cells, was used
for the challenge of mice on day 28 after the booster
immunization. The recNP immunized, adjuvant control and
PBS control mice were inoculated s.c. with 100 mlo f1 0
7.0
TCID50/ml RVFV, whereas the age related control group of mice
were ‘‘mock’’ challenged with 100 ml uninfected Vero cell culture
supernatant. Mice were monitored twice daily for clinical signs.
Three mice were randomly collected from each group,
euthanized by CO2 asphyxiation and liver and spleen tissues
collected at the following time points after RVFV challenge: 3, 6,
12, 24, 72 and 120 hours. A piece of approximately 50 mg of each
tissue was collected into an RNA stabilization reagent (RNAlater,
Qiagen, Germany) according to the instructions of the manufac-
turer, and stored at 270uC until further processing. The
remaining tissue was stored in cryotubes at 270uC for viral load
determination.
Virus titrations
Liver and spleen tissues were homogenized as 10% (w/v)
suspensions in EMEM containing L-glutamine, non-essential
amino acids and antibiotics (100 IU penicillin, 100 mg streptomy-
cin and 0.25 mg amphotericin B) using a Tissuelyser II and 5 mm
stainless steel beads (Qiagen, Germany) according to the
manufacturer’s instructions (4 min, 25 Hz). After centrifugation
at 10,0006 g for 3 minutes the supernatants were collected and
stored at 270uC until tested. Titrations were performed as
described previously [17]. Virus titers, calculated by the Ka ¨rber
method [105], were expressed as median tissue culture infectious
dose (TCID50) per gram of tissue. Means and standard deviations
from the means were determined based on three animals per
group per each time point tested.
RNA extraction
The tissues were moved from RNAlater into lysis buffer (Buffer
RLT, Qiagen, Germany) and lysis-homogenization performed by
using a Tissuelyser II as described above. Lysates were centrifuged
for 3 minutes at 13,200 rpm at room temperature and superna-
tants collected. Extraction of RNA from the supernatants was
performed by using the RNeasy Mini Kit (Qiagen, Germany). A
50% ethanol was used to increase RNA yield from livers and 70%
ethanol for spleens as suggested by the manufacturer, followed by
on-column Dnase digestion using the Rnase-free Dnase set
(Qiagen, Germany), to remove genomic DNA. The RNA was
eluted in Rnase-free water, the concentration determined using a
NanoDrop ND-1000 spectrophotometer (Thermo Scientific,
U.S.A) and stored at 270uC until further testing.
For testing with the SABiosciences quantitative PCR array (as
described below), further RNA cleanup was performed on RNA
already extracted from livers and spleens collected at 72 hours post
infection, as per the manufacturer’s instructions. This cleanup,
which introduces an additional Dnase digestion, was performed
using the RT
2 qPCR-Grade RNA Isolation Kit (SABiosciences,
Qiagen, U.S.A) as per the manufacturer’s instructions. The RNA
was eluted in Rnase-free water, the concentration determined
using a NanoDrop ND-1000 spectrophotometer (Thermo Scien-
tific, U.S.A) and stored at 270uC until further testing.
Quantitect qRT-PCR
The RNA extracted from all experimental mice at all time
points after RVFV challenge were diluted to 10 ng/ml and used in
the qRT-PCR reactions. The Quantitect qRT-PCR reactions
were performed as described by the manufacturer (Quantifast
SYBR Green RT-PCR kit, Qiagen, Germany) using a Lightcycler
1.5 (Roche, Germany). Briefly, a reaction mix was prepared by
mixing 26 Quantifast SYBR Green RT-PCR Master Mix
(HotStarTaq Plus DNA Polymerase, Quantifast SYBR Green
RT-PCR buffer, dNTP mix and ROX passive reference dye), 106
Quantitect Primer set (for detection of the genes for Gapdh, Il10,
Ifng and Ifnb1), Quantifast RT-Mix (Omniscript RT and
Sensiscript RT), template RNA (10 ng) and RNase-free water to
a final volume of 20 ml per reaction. This mix was transferred to
20 ml Lightcycler Capillaries (Roche, Germany) and run on the
Lightcycler 1.5 using the following cycles: 16reverse transcription
(10 min, 50uC), 16 hotstart PCR activation (5 min, 95uC) and
406 cycles of denaturation (10 sec, 95uC) and annealing/
extension (30 sec, 60uC), with fluorescence data collection just
after the annealing/extension step. The threshold cycle (CT) values
were determined using the second derivative maximum method
(Lightcycler Data Analysis Software version 3.5.28, Roche). The
CT values were then used for relative quantification (as described
below).
RNA was extracted from the liver and spleen of a normal
BALB/cOlaHsd mouse to generate standard curves in order to
determine PCR reaction efficiencies (necessary for the relative
quantification calculations) with primer sets for different genes
(GAPDH, IL-10, IFNa ˜ and IFNa ˆ1). Dilution series were prepared
and the following amounts of RNA tested in duplicate using all
primer sets: 30 ng; 15 ng, 7.5 ng, 3.75 ng and 1.875 ng. The CT
values and their corresponding template amount values were then
used to determine the PCR reaction efficiencies using the Relative
Expression Software Tool (REST, Qiagen, Germany) [106] as
described by the manufacturer (results not shown).
Relative quantification data analysis (Quantitect qRT-PCR)
Threshold values (CT) from biological triplicates for the different
genes analyzed as determined for the immunized mice, adjuvant
control and PBS control mice were first normalized to the CT
values of the housekeeping gene (Gapdh) analyzed in the same
samples, and further normalized to the CT values from the non-
infected control mice to determine the relative changes in gene
expression compared to age related normal mice. This is the so-
called 2
2DDCt and the result is a fold change value that is an
indication of the expression level of a gene in the experimental
group being higher or lower than the expression level in the
normal age-related control group [107]. These calculations were
done using the REST software (Qiagen, Germany) which uses the
PCR efficiencies for different primer sets (as determined above,
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The negative inverted values were determined (i.e. 0.5=
1/20.5=22.0) for fold change values smaller than one (,1).
Genes were only regarded as upregulated with fold changes $2.0,
and downregulated with fold changes #22.0, based on the same
cut-off values used in a recent study [33].
SABioscienes quantitative PCR array
The RNA extracted with the RT
2 qPCR-Grade RNA Isolation
Kit from liver and spleen collections of all mice at 72 hours post
infection were diluted to 150 ng/ml in nuclease free water.
Complementary DNA (cDNA) was prepared from the RNA using
the RT
2 First Strand kit (SABiosciences, Qiagen, U.S.A) as
described by the manufacturer. A total of 1.2 mg of each RNA
preparation was mixed with 56genomic DNA Elimination buffer
and the reaction incubated at 42uC for 5 minutes (total volume
10 ml). After the incubation, the reactions were immediately
moved to ice and, subsequently, an equal volume of RT-coctail
mix added (56RT buffer, primers and external control mix, RT-
enzyme mix and RNase-free water). These reactions were then
incubated at 42uC for 15 minutes and 95uC for 5 minutes. The
resultant cDNA of each preparation was then diluted 1:10 with
nuclease-free water and stored at 220uC until tested.
The 1:10 diluted cDNA was mixed with the master mix (26
SABiosciences RT
2 qPCR Master Mix) and nuclease-free water,
and aliquoted onto the PCR array plates containing primer sets
(listed in Table S1)(25 ml of reaction mix per well)(PAMM-053,
SABiosciences, Qiagen, Germany). Plates were run on an ABI
7500 cycler (Applied Biosystems, U.S.A). The following cycling
program was used: 1695uC for 10 minutes, 40695uC for
15 seconds and 60uC for 1 minute, followed by the default
melting curve program. Fluorescence was measured just after the
1 minute/60uC step. The cycle threshold (CT) values were
determined using the cycler software and an automatic baseline
adjustment (ABI 7500 Software Version 2.0.1, Applied Biosys-
tems, U.S.A). Three mice per group were analyzed and average
values calculated.
Relative quantification data analysis (SABioscienes
quantitative PCR array)
Calculation of fold change values from the results of the
SABiosciences quantitative PCR array relies essentially on the
same principles as for the Quantitect qRT-PCR, making use of the
2
2DDCt method, except for the use of up to 5 housekeeping genes
(Gusb, Hprt1, Hsp90ab1, Gapdh and Actb) for normalization of
data. These calculations were done using the SABiosciences PCR
Array Data Analysis Template Excel Utility (http://sabiosciences.
com/pcrarraydataanalysis.php)(Qiagen, Germany). The negative
inverted values were determined (i.e. 0.5=
1/20.5=22.0) for fold
change values smaller than one (,1). Genes were only regarded as
upregulated with fold changes $2.0, and downregulated with fold
changes #22.0.
Statistical analysis
The REST software uses a Pair-Wise Fixed Reallocation
Randomization Test [106] with 2000 randomizations to
determine a P-value which gives an indication of the statistical
significance of fold changes. The SABiosciences PCR Array Data
Analysis Template Excel Utility incorporates the calculation of a
P-value using a T-test. Fold changes with P-values smaller or equal
to 0.05 (#0.05) were taken as statistically significant. Three
biological replicates were used at all experimental time points in all
groups to enable statistical reliability of results.
Supporting Information
Table S1 Fold change in expression of 84 genes involved
in activation of B- and T-cell immunity. Fold changes are
shown for immunized mice versus non-immunized control mice
(n=3 per group) after RVFV challenge at 72 hours in liver,
relative to expression in an age-related control group of mice
(n=3).
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